$SPRB
SPRUCE BIOSCIENCES, INC.

2021 Q1 Form 10-Q Financial Statement

#000156459021027012 Filed on May 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.100M
YoY Change
% of Gross Profit
Research & Development $6.714M $4.610M
YoY Change 45.64%
% of Gross Profit
Depreciation & Amortization $13.00K $1.000K
YoY Change 1200.0%
% of Gross Profit
Operating Expenses $9.817M $5.133M
YoY Change 91.25%
Operating Profit -$9.817M -$5.133M
YoY Change 91.25%
Interest Expense $89.00K $74.00K
YoY Change 20.27%
% of Operating Profit
Other Income/Expense, Net $19.00K $39.00K
YoY Change -51.28%
Pretax Income -$9.890M
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$9.887M -$5.168M
YoY Change 91.31% 25.47%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$424.8K
COMMON SHARES
Basic Shares Outstanding 23.30M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $148.6M
YoY Change
Cash & Equivalents $148.6M $41.41M
Short-Term Investments
Other Short-Term Assets $272.0K
YoY Change
Inventory
Prepaid Expenses $2.687M
Receivables
Other Receivables
Total Short-Term Assets $151.6M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $1.700M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $473.0K
YoY Change
Total Long-Term Assets $2.405M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $151.6M
Total Long-Term Assets $2.405M
Total Assets $154.0M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.566M
YoY Change
Accrued Expenses $4.300M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $6.851M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $4.843M
YoY Change
Other Long-Term Liabilities $8.000K
YoY Change
Total Long-Term Liabilities $4.851M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $6.851M
Total Long-Term Liabilities $4.851M
Total Liabilities $13.27M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$70.73M
YoY Change
Common Stock $211.5M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $140.7M -$35.77M
YoY Change
Total Liabilities & Shareholders Equity $154.0M
YoY Change

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$9.887M -$5.168M
YoY Change 91.31% 25.47%
Depreciation, Depletion And Amortization $13.00K $1.000K
YoY Change 1200.0%
Cash From Operating Activities -$8.787M -$5.956M
YoY Change 47.53%
INVESTING ACTIVITIES
Capital Expenditures $19.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$19.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $4.770M
YoY Change
Cash From Financing Activities 283.0K 43.66M
YoY Change -99.35%
NET CHANGE
Cash From Operating Activities -8.787M -5.956M
Cash From Investing Activities -19.00K
Cash From Financing Activities 283.0K 43.66M
Net Change In Cash -8.523M 37.70M
YoY Change -122.61%
FREE CASH FLOW
Cash From Operating Activities -$8.787M -$5.956M
Capital Expenditures $19.00K
Free Cash Flow -$8.806M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2687000
CY2021Q1 us-gaap Other Assets Current
OtherAssetsCurrent
272000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1716000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
477000
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Assets
Assets
162883000
CY2021Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
211449000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3628000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1653000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
118000
CY2020Q4 us-gaap Liabilities
Liabilities
13456000
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q1 us-gaap Assets Current
AssetsCurrent
151586000
CY2021Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
216000
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
473000
CY2021Q1 us-gaap Assets
Assets
153991000
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2566000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2554000
CY2021Q1 sprb Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
3558000
CY2020Q4 sprb Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
2496000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
210266000
CY2021Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
727000
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1085000
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
6851000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9763000
CY2021Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4843000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1922000
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1566000
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
8000
CY2021Q1 us-gaap Liabilities
Liabilities
13268000
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
2000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-70728000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-60841000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
140723000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
149427000
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
153991000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
162883000
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23301872
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23260399
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23301872
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23260399
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6714000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4610000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3103000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
523000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
9817000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
5133000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-9817000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5133000
CY2021Q1 us-gaap Interest Expense
InterestExpense
89000
CY2020Q1 us-gaap Interest Expense
InterestExpense
74000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
19000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
39000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-9887000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-5168000
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.42
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-6.76
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23283658
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
764408
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
63000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1120000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-30637000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
32000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-35773000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-9887000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-5168000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1120000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
32000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
13000
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
77000
CY2021Q1 sprb Increase Decrease In Prepaid Expenses And Other Current Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
-291000
CY2020Q1 sprb Increase Decrease In Prepaid Expenses And Other Current Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
-56000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-82000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-269000
CY2021Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-358000
CY2020Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-685000
CY2021Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-16000
CY2020Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-36000
CY2021Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
23000
CY2020Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
41000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8787000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5956000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
19000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-19000
CY2020Q1 us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
43655000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
63000
CY2021Q1 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
4990000
CY2021Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
4770000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
283000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
43655000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-8523000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
37699000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
157366000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3924000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
148843000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
41623000
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
54000
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
46000
CY2021Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
10000
CY2020Q1 sprb Operating Lease Commencement Month And Year
OperatingLeaseCommencementMonthAndYear
2020-09
CY2020Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P63M
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses as well as related disclosure of contingent assets and liabilities. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, accrued research and development expenses, valuation of common stock and stock-based compensation and income tax and uncertain tax positions. The Company bases its estimates on its historical experience and on assumptions that it believes are reasonable; however, actual results could significantly differ from those estimates.</p>
CY2020Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P60M
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
110000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
8800000
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41407000
CY2021Q1 us-gaap Restricted Cash
RestrictedCash
216000
CY2020Q1 us-gaap Restricted Cash
RestrictedCash
216000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
148843000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41623000
CY2021Q1 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
5000000
CY2021Q1 sprb Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
2864000
CY2020Q4 sprb Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
2002000
CY2021Q1 sprb Accrued General And Administrative Expenses
AccruedGeneralAndAdministrativeExpenses
362000
CY2020Q4 sprb Accrued General And Administrative Expenses
AccruedGeneralAndAdministrativeExpenses
245000
CY2020Q1 sprb Lease Gross Commitment Amount
LeaseGrossCommitmentAmount
2300000
CY2021Q1 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The lease includes an option to renew the lease term for an additional period of 60 months. The renewal option is not included in the lease term or minimum lease payments disclosures below as the Company is not reasonably certain to exercise the option.
CY2020Q1 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
332000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
249000
CY2021Q1 sprb Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercised Shares
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedShares
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
900000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1120000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
32000
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
11900000
CY2019Q1 sprb Operating Lease Commencement Month And Year
OperatingLeaseCommencementMonthAndYear
2019-03
CY2019Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P12M
CY2019Q1 us-gaap Short Term Lease Commitment Amount
ShortTermLeaseCommitmentAmount
200000
CY2020Q1 sprb Lessee Operating Lease Extended Term Of Contract
LesseeOperatingLeaseExtendedTermOfContract
P3M
CY2020Q1 sprb Short Term Lease Additional Commitments
ShortTermLeaseAdditionalCommitments
42000
CY2021Q1 sprb Lessee Operating Lease Termination Date
LesseeOperatingLeaseTerminationDate
2020-05
CY2020Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
42000
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y8M12D
CY2021Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.070
CY2021Q1 sprb Cash Paid For Amounts Included In Measurement Of Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities
37000
CY2021Q1 us-gaap Variable Lease Cost
VariableLeaseCost
2000
CY2021Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
5000000
CY2021Q1 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
157000
CY2021Q1 us-gaap Long Term Debt
LongTermDebt
4843000
CY2021Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2021Q1 sprb Aggregate License Agreement Amount
AggregateLicenseAgreementAmount
23000000
CY2021Q1 sprb Additional Aggregate License Agreement Amount
AdditionalAggregateLicenseAgreementAmount
0
CY2021Q1 us-gaap Legal Fees
LegalFees
0
CY2021Q1 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one vote
CY2021Q1 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2021Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6490636
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5136487
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
Following the effectiveness of the 2020 Plan, no further grants will be made under the 2016 Plan; however, shares subject to awards granted under the 2016 Plan continue to be governed by the 2016 Plan. Any shares subject to outstanding stock options or other stock awards that were granted under the 2016 Plan that terminate or expire prior to exercise or settlement; are settled in cash; are forfeited or repurchased because of the failure to vest; or are reacquired or withheld to satisfy a tax withholding obligation or the purchase or exercise price in accordance with the terms of the 2016 Plan will also be reserved for issuance under the 2020 Plan.
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y6M
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2612416
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10726020

Files In Submission

Name View Source Status
0001564590-21-027012-index-headers.html Edgar Link pending
0001564590-21-027012-index.html Edgar Link pending
0001564590-21-027012.txt Edgar Link pending
0001564590-21-027012-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sprb-10q_20210331.htm Edgar Link pending
sprb-20210331.xml Edgar Link completed
sprb-20210331.xsd Edgar Link pending
sprb-20210331_cal.xml Edgar Link unprocessable
sprb-20210331_def.xml Edgar Link unprocessable
sprb-20210331_lab.xml Edgar Link unprocessable
sprb-20210331_pre.xml Edgar Link unprocessable
sprb-ex311_7.htm Edgar Link pending
sprb-ex312_9.htm Edgar Link pending
sprb-ex321_8.htm Edgar Link pending
sprb-ex322_6.htm Edgar Link pending